Skip to main content
Fig. 5 | BMC Gastroenterology

Fig. 5

From: The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis

Fig. 5

Summary of pooled results including the HBsAG loss rate in ETV plus Tα1 group and ETV alone group. “Events” represents the number of subjects experiencing a HBsAG loss. “Total” represents the number of subjects in that group. “Test for overall effect” represents the pooled estimate of risk ratio after comprehensive analysis of all studies. Blue boxes indicate the dichotomous data in the forest plots. CI, confidence interval; M-H, Mantel-Haensel

Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us